Strategy construction to minimize the limitation of respiratory viral vaccine development


Review Article

Author Details : Rudra Prasad Roy*, Laxmi Devi

Volume : 9, Issue : 1, Year : 2022

Article Page : 1-8

https://doi.org/10.18231/j.ijmr.2022.001



Suggest article by email

Get Permission

Abstract

Recent outbreak by the coronavirus SARS-CoV-2 is a major global public threat. Similarly, for several years other coronaviruses, RSV or Influenza viruses are also equally showing risk to the worldwide population. Therefore, several countries have been given tremendous efforts to generate an effective vaccine against respiratory viral infections. It is very important to understand the attributes of a protective mucosal antiviral immune response for the development of a vaccine for respiratory viral infections. Characteristics of the mucosal immune system and evolution of the mucosal vaccine play an important role in protection against respiratory viral infection. Memory CD8 T cell populations play a crucial role in making high levels of gamma interferon and tumour necrosis factor may be essential for protection. Whereas developed vaccines of respiratory infections continue to fail in effectively generating long-lived protective immunity. Hence, memory CD8 T cell can elicit long-lived immunity, and immunostimulatory adjuvants such as OX40, OX40L or IL12 can enhance the memory CD8 T cell. Viroporin on the other hand use as a vaccine candidate to avoid viral mutation, as a result, the present review work was constructed for a novel combination i.e., immune adjuvant with newly viral antigenic gene or vaccine candidate that can fulfill the limitation of vaccine development for respiratory infection.
 

Keywords: Immunostimulatory adjuvant, Viroporin, Respiratory viral vaccine


How to cite : Roy R P, Devi L, Strategy construction to minimize the limitation of respiratory viral vaccine development. Indian J Microbiol Res 2022;9(1):1-8


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.







Article History

Received : 07-10-2021

Accepted : 20-12-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijmr.2022.001


Article Metrics






Article Access statistics

Viewed: 784

PDF Downloaded: 430



Medical Abbreviation List